120 related articles for article (PubMed ID: 6775094)
21. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women.
Lobo RA; McCormick W; Singer F; Roy S
Obstet Gynecol; 1984 Jan; 63(1):1-5. PubMed ID: 6318170
[TBL] [Abstract][Full Text] [Related]
22. [Effect of medroxyprogesterone (MPA) on blood levels of FSH, LH and prolactin in women].
Kotarski J; Jakowicki J
Ginekol Pol; 1985 Oct; 56(10):581-4. PubMed ID: 2936657
[No Abstract] [Full Text] [Related]
23. Climacteric flushing: clinical and endocrine response to infusion of naloxone.
Lightman SL; Jacobs HS; Maguire AK; McGarrick G; Jeffcoate SL
Br J Obstet Gynaecol; 1981 Sep; 88(9):919-24. PubMed ID: 6791684
[TBL] [Abstract][Full Text] [Related]
24. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
25. The use of medroxyprogesterone acetate for relief of climacteric symptoms.
Morrison JC; Martin DC; Blair RA; Anderson GD; Kincheloe BW; Bates GW; Hendrix JW; Rivlin ME; Forman EK; Propst MG; Needham R
Am J Obstet Gynecol; 1980 Sep; 138(1):99-104. PubMed ID: 7416212
[TBL] [Abstract][Full Text] [Related]
26. Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol, and estrone in patients with endometrial carcinoma.
Vesterinen E; Backas NE; Pesonen K; Stenman UH; Laatikainen T
Arch Gynecol; 1981; 230(3):205-11. PubMed ID: 6787991
[TBL] [Abstract][Full Text] [Related]
27. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period.
Haas S; Walsh B; Evans S; Krache M; Ravnikar V; Schiff I
Obstet Gynecol; 1988 May; 71(5):671-6. PubMed ID: 3357653
[TBL] [Abstract][Full Text] [Related]
28. Clinical and endocrinological features of statistical clusters of women with climacteric symptoms.
Abe T; Suzuki M; Wada Y; Yamaya Y; Moritsuka T
Tohoku J Exp Med; 1985 May; 146(1):59-68. PubMed ID: 3927516
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
30. Suppression of urinary excretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by medroxyprogesterone acetate.
Rifkind AB; Kulin HE; Cargille CM; Rayford PC; Ross GT
J Clin Endocrinol Metab; 1969 Apr; 29(4):506-13. PubMed ID: 4888564
[No Abstract] [Full Text] [Related]
31. Double-blind crossover clinical pharmacology study comparing moxestrol (R 2858) and ethinyl estradiol in postmenopausal women.
Robyn C; Vekemans M; Rozencweig M; Chigot D; Raynaud JP
J Clin Pharmacol; 1978 Jan; 18(1):29-34. PubMed ID: 338643
[TBL] [Abstract][Full Text] [Related]
32. [Assessment of serum estrogen levels by RIA with HPLC during hormone replacement therapy].
Yasui T; Uemura H; Yoneda N; Irahara M; Aono T; Sunahara S; Hata K
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jul; 47(7):655-61. PubMed ID: 7636337
[TBL] [Abstract][Full Text] [Related]
33. Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome.
Wortsman J; Hirschowitz JS
Obstet Gynecol; 1980 Apr; 55(4):460-3. PubMed ID: 6768040
[TBL] [Abstract][Full Text] [Related]
34. Induced prolactin release in women under long-term medroxyprogesterone acetate treatment.
Perez-Lopez FR; Roncero MC
Obstet Gynecol; 1975 Mar; 45(3):263-6. PubMed ID: 803668
[TBL] [Abstract][Full Text] [Related]
35. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
Prior JC; Nielsen JD; Hitchcock CL; Williams LA; Vigna YM; Dean CB
Clin Sci (Lond); 2007 May; 112(10):517-25. PubMed ID: 17419685
[TBL] [Abstract][Full Text] [Related]
36. The effects of progestins on vasomotor flushes.
Schiff I
J Reprod Med; 1982 Aug; 27(8 Suppl):498-502. PubMed ID: 7131442
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial.
Cravioto MD; Durand-Carbajal M; Jiménez-Santana L; Lara-Reyes P; Seuc AH; Sánchez-Guerrero J
Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1654-63. PubMed ID: 22127965
[TBL] [Abstract][Full Text] [Related]
38. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
39. No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial.
Prior JC; Alojado N; McKay DW; Vigna YM
Obstet Gynecol; 1994 Jan; 83(1):24-8. PubMed ID: 8272302
[TBL] [Abstract][Full Text] [Related]
40. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
